EHA 2022 | CD7 gene knockout CAR-T cell therapy for R/R T-cell hematological malignancies
Peihua Lu
• 16 Jun 2022
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, and Hebei Yanda Lu Daopei Hospital, Langfang, China, discusses a Phase I clinical trial evaluating the safety and efficacy of CD7 gene knockout CAR-T cell therapy for relapsed/refractory (R/R) T-cell malignancies. Dr Lu discusses some results from this trial, which demonstrated that 100% of patients achieved a deep measurable residual disease (MRD) negative complete remission (CR) in bone marrow and blood. Dr Lu highlights the promise of these results and the need for further investigation through clinical trials. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
